

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Currently amended) A method for treating a patient suffering from one or more insulin related ailments selected from the group consisting of hyperglycemia, ~~hypoglycemia~~ diabetes mellitus, ~~insulinomas, insulin and hypoglycemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism,~~ and Alzheimer's disease, which method comprises the step of: administering to a patient in need thereof a therapeutically effective amount of a non-peptidyl compound, which possesses one or more ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location of at least an ionic or a hydrophobic amino acid residue of insulin, wherein said compound is an insulin agonist.
2. (Previously presented) A method according to claim 1, wherein the ionic amino acid residue is selected from the group consisting of: A21 Asn, B21 Glu and A17 Glu.
3. (Original) A method according to claim 1, wherein the ionic and hydrophobic amino acid residue(s) is(are) selected from the group consisting of: A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr, A2 Ile, A3 Val and A1 Gly.
4. (Previously presented) A method according to claim 1, wherein at least one amino acid is selected from the group consisting of: A17 Glu, B21 Glu and A21 Asn; and at least one amino acid is selected from the group consisting of: B24 Phe, B25 Phe, A19 Tyr, B12 Val and B16 Tyr.
5. (Previously presented) A method according to claim 1, wherein the non-peptidyl compound possesses ionic and hydrophobic chemical moieties spatially located so as to mimic ionic and hydrophobic residues associated with at least one of the following groups of amino acid residues:
 - (i.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe;
 - (ii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe;
 - (iii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A1 Gly, A2 Ile, A3 Val;
 - (iv.) A21 Asn, B21 Glu, A17 Glu, A19 Tyr, A1 Gly, A2 Ile, A3 Val;

- (v.) A21 Asn, B21 Glu, A17 Glu, B12 Val, A1 Gly, A2 Ile, A3 Val;
- (vi.) A21 Asn, B21 Glu, B12 Val, A1 Gly, A2 Ile, A3 Val;
- (vii.) A21 Asn, B21 Glu, A17 Glu, B16 Tyr, A1 Gly, A2 Ile, A3 Val;
- (viii) A21 Asn, B21 Glu, A17 Glu, A19 Tyr, B12 Val, B16 Tyr;
- (ix.) A21 Asn, B21 Glu, A19 Tyr, B12 Val, B16 Tyr;
- (x.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xi.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xii) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B12 Val, B16 Tyr;
- (xiii.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xiv.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xv.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xvi.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xvii.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, B12 Val;
- (xviii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B12 Val;
- (xix.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, B12 Val;
- (xx.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, B12 Val;
- (xxi.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxiii.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxiv.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxv.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxvi.) A21 Asn, B21 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxvii.) A21 Asn, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxviii.) B21 Glu, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxix.) A21 Asn, B21 Glu, A17 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;

(xxx.) A21 Asn, B21 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;

(xxxi.) A21 Asn, A17 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr; and

(xxxii.) B21 Glu, A17 Glu, B25 Phe, A19 Tyr, B12 Val.

6. (Currently amended) A method according to claim 1, wherein the non-peptidyl compound has the following formula:



where A is W or VXW;

V is V_1 or V_2 ;

V is substituted with up to two X groups;

V_1 is a phenyl or 6 membered heteroaromatic ring, optionally substituted with up to 5 R_1 groups;

V_2 is a 5 member ring system which may incorporate up to 4 hetero atoms which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the ring system being optionally substituted with up to 4 R_1 groups;

W is W_1 or W_2 or W_3 ;

W is substituted with up to two X groups;

W_1 is V_1 ;

W_2 is a fused bicyclic ring system comprising rings of 5 or 6 atoms, which may incorporate up to 4 hetero atoms, which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the system being optionally substituted with up to seven R_1 groups;

W_3 is $-\text{N}(\text{R}_2)\text{R}'_2$;

R_1 is independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, haloalkyl, haloalkoxy, halogen, SH, thioalkyl, cyano (-CN), $\text{N}(\text{R}_2)\text{R}'_2$, phenyl, phenyl optionally substituted with up to five alkyl groups of 1 to 3 carbon atoms or up to five halogen atoms, benzyl, phenethyl, nitro, $-\text{COR}_3$, $-\text{R}_5\text{COR}_3$, $-\text{R}_5\text{SOR}_3$, $-\text{R}_5\text{SO}_2\text{R}_3$, $-\text{SO}_2\text{N}(\text{R}_2)\text{R}'_2$ or azido;

R_2 and R'_2 are independently H, alkyl of 1 to 6 carbon atoms, alkenyl of 3 to 6 carbon atoms, alkynyl of 3 to 6 carbons, hydroxyalkyl of 2 to 6 carbons, alkoxy of 2 to 6 carbons, haloalkyl, haloalkenyl, haloalkoxy, benzyl, benzyl optionally

substituted with up to four R_1 groups, phenylethyl, phenylethyl optionally substituted with up to four R_1 groups, arylalkyl, and where R_2 and R'_2 can also be joined to form cyclic structures;

R_3 is independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, $-R_4N(R_2)R'_2$, mesyl, trifluoromesyl, $-NHSO_2CH_3$ or $-NHSO_2CF_3$;

R_4 is independently a bond, alkyl, alkenyl or alkynyl;

X is independently, a bond, $-R_4N(R_2)R_4-$, $-R_4N=NR_4-$, $-R_4N(R_2)-N(R_2)R_4-$, $-R_4OR_4-$, $-R_4SR_4-$, $-R_5-$, $-R_5O-$, $-R_5S-$, $-R_5N(R_2)-$, $-SO-$, sulfonyl ($-SO_2-$), $-CO-$, $-CONH-$, $-NHCONH-$, $-NHCO-$, $-CONHCO-$, $-CON(R_2)-$, $-R_5COR_5-$, $-R_5COR_5N(R_2)R_5-$, $-N(R_2)CO-$ or $-R_4N(R_2)R_4COR_4-$;

R_5 is independently alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy;

Y is either Y_1 , Y_2 or Y_3 ;

Y is substituted with at least two, but optionally up to four X linking groups;

Y_1 is a fused bicyclic ring system comprising rings of 5 or 6 atoms which may incorporate up to 4 hetero atoms, which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the ring system optionally independently incorporating a sulfoxide (SO), sulfone (SO_2) or carbonyl (CO) group and optionally up to seven R_1 groups;


Y_2 is a 6:6:6 or a 6:5:6 fused tricyclic system which may incorporate up to 4 hetero atoms which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the ring system optionally independently incorporating a sulfoxide (SO), sulfone (SO_2) or carbonyl (CO) group, and the ring system being substituted with at least two, but optionally up to four X linking groups and optionally up to seven R_1 groups;

Y_3 is V_1 ;

Z is independently $-R_6COOH$, $-R_6SO_3H$, $-R_6NO_2$, $-R_6SO_2H$, $-R_6SO_2NHR_2$;

$-R_7SO_2NHCOR_4$, N-trifluoromesylsulfonamidate, $-OH$, 2-yl-hydroxyethanoic acid ($-CH(OH)COOH$), 3-yl-2-hydroxypropanoic acid ($-CH_2CH(OH)COOH$), 2-yl-2-hydroxypropanoic acid ($-CH(CH_3)(OH)COOH$), 3-yl-2,3-dihydroxypropanoic acid ($-CH(OH)CH(OH)COOH$), 2-yl-2,3-dihydroxypropanoic acid ($-C(CH_2(OH))(OH)COOH$), 3-yl-2-hydroxypropan-3-one-1-oic acid

(-COCH(OH)COOH, 2-yl-2-hydroxypropandioic acid (-C(COOH)(OH)COOH), -2-yl-propandioic acid (-C(COOH)(H)COOH), -4-yl-2-hydroxybutan-4-one-1-oic acid (-COCH₂CH(OH)COOH, 2-yl-2-hydroxybutan-1,4-dioic acid (-C(OH)(COOH)CH₂COOH), 3-yl-2-hydroxybutan-1,4-dioic acid (-CH(CH(OH)COOH)COOH), 5-yl-tetrazole,



R₆ is independently a bond, alkyl, alkenyl, alkynyl, alkoxy, -CO(CH₂)_n-, where n is an integer between 0 and 4, alkanolic, alkenolic or alkynolic;

with the exception that where W₁ is an optionally substituted phenyl then Y₃ cannot be an optionally substituted phenyl.

7. (Original) A method according to claim 6, wherein the non-peptidyl compound is a dimer or heterodimer wherein the compounds are joined through a X linking group by way of their V or W groups.

8. (Currently amended) A method according to claim 6, wherein when V is V₁ or V₂, then:

V₁ is selected from the group consisting of, benzene, pyridine, pyridazine, pyrimidine, pyrazine ~~or~~ and triazine and is optionally substituted with up to 5 R₁ groups; and

V₂ is selected from the group consisting of, cyclopenta-1,3-diene, pyrrole, furan, thiophene, oxazole, isoxazole, pyrazole, imidazole, thiazole, isothiazole ~~or~~ and triazole and is optionally substituted with up to 4 R₁ groups;

and W is W₂ then

W₂ is selected from the group consisting of naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, indole, benzothiophene, benzofuran, benzimidazole, indazole, benzoxazole, benzisooxazole, benzthiazole, benzisothiazole, purine, indoline ~~or~~ and isoindoline and is optionally substituted with up to seven R₁ groups;

and Y is either Y₁ or Y₂ then

Y₁ is selected from the group consisting of croman, isochroman, benzofuran, cromene, 1,2,3,4-tetrahydronaphthalene, 1,4-dihydronaphthalene, indan, indene, benzopiperidine, indoline, isoindoline, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline or pteridine, coumarin or and 2,3-dihydrocoumarin and is optionally substituted with up to seven R₁ groups; and Y₂ is selected from the group consisting of 9H-xanthone, 9H-xanthene, phenoxathiin, phenoxathiin-10-oxide, phenoxathiin-10-dioxide, acridine, phenazine, phenothiazine, phenoxazine, phenothiazine-5-oxide, phenothiazine-5-dioxide, thiathrene-5-dioxide, thiathrene-5-oxide, carbazole, dibenzo[b,d]furan or and dibenzo[b,d]thiophene and is optionally substituted with up to seven R₁ groups.

9. (Original) A method according to claim 6, wherein when A is VXW then: V is phenyl or pyrazole, optionally substituted with up to 5 R₁ groups; and when A is W or VXW then W is W₁, W₂ or W₃ wherein W₁ is phenyl optionally substituted with up to 5 R₁ groups;

W₂ is naphthalene or quinoline optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

W₃ is -N(R₂)R₂ wherein R₂ is propyl; X is independently, a bond, methoxy (-OCH₂-), oxypropoxy (-O(CH₂)₃O-), hexenyloxy (-O(CH₂)₄CH=CH-), sulfonyloxy (-SO₂O-), methyl (-CH₂-), amidyl (-CONH-) or -NHCONH-; and Y is either Y₁ or Y₂ then Y₁ is croman, 4-H-chromen-4-one or naphthalene optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

Y₂ is 9H-xanthone optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

Y_3 is phenyl optionally substituted with up to 5 R_1 groups wherein R_1 is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl; and
 Z is independently $-R_6COOH$, $-R_6SO_3H$ or $-N$ -trifluoromethylsulfonamide wherein R_6 is independently a bond or propyl.

10. (Currently amended) A method according to claim 6, wherein the non-peptidyl compound is selected from the following group of compounds:

- (i.) 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylic acid];
- (ii.) 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid;
- (iii.) 2,4-dichloro-6-(*N*-(trifluoromethanesulfonyl))sulfamoylphenyl 3,5-dichloro-2-hydroxybenzenesulfonate;
- (iv.) 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl-4*H*-1-benzopyran-2-carboxylic acid;
- (v.) 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2*H*-1-benzopyran-2-carboxylic acid;
- (vi.) 3,4-dihydro-8-propyl-7-[[3-[2-ethyl-5-hydroxy-4-(1*H*-pyrazol-3-yl)phenoxy]propyl]oxy]-2*H*-1-benzopyran-2-carboxylic acid;
- (vii.) 3,4-dihydro-8-propyl-7-[[3-[2-ethyl-5-hydroxy-4-ethoxyphenoxy]propyl]oxy]-2*H*-1-benzopyran-2-carboxylic acid;
- (viii.) 3-[4-[7-carboxy-9-oxo-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9*H*-xanthene]]propanoic acid; or
- (ix.) 8-propyl-7-(quinol-2'-ylmethoxy)-3,4-dihydro-2*H*-1-benzopyran-2-carboxylic acid;
- (x.) 7-(naphth-2'-ylmethoxy)-8-propyl-3,4-dihydro-2*H*-1-benzopyran-2-carboxylic acid;
- (xi.) *N*-(trifluoromethanesulfonyl)-3,5-dinitro-4-(*N,N'*-dipropylamino)benzenesulfonamide;
- (xii.) 8-propyl-7-[3-[4-(4-fluorophenyl)-2-ethyl-5-hydroxyphenoxy]propoxy]-3,4-dihydro-2*H*-1-benzopyran-2-carboxylic acid;

(xiii.) 3,4-dihydro-7-[[6-(4-methoxyphenyl)hexenyl]oxy]-8-propyl-2H-1-benzopyran-2-carboxylic acid; ~~or~~ and

(xiv.) 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid.

11-15 (Canceled)

16. (Previously presented) A method for identifying a non-peptidyl compound possessing ionic and hydrophobic chemical moieties spatially located so as to mimic particular ionic and hydrophobic amino acid residues of insulin, said method comprising the steps of: (1) comparing the three dimensional structure of the non-peptidyl compound with a three dimensional pharmacophore of an active site of insulin; and (2) selecting a non-peptidyl compound with ionic and hydrophobic chemical moieties spatially located so as to mimic said site.

17. (Original) A method for determining whether a non-peptidyl compound identified according to the method of claim 16 is an agonist or an antagonist, said method comprising the step of: exposing the compound to an insulin or insulin like receptor and measuring the change in biological activity following exposure of the compound to the receptor.

18-19. (Canceled)

20. (Currently amended) A method according to claim 6 wherein V_1 is selected from the group consisting of: benzene, pyridine, pyridazine, pyrimidine, pyrazine[[,]] and triazine.

21. (Currently amended) A method according to claim 6 wherein V_2 is selected from the group consisting of: cyclopenta-1,3-diene, pyrrole, furan, thiophene, oxazole, isoxazole, pyrazole, imidazole, thiazole, isothiazole ~~or~~ and triazole, optionally substituted with up to 4 R_1 groups.

22. (Currently amended) A method according to claim 6 wherein W_2 is selected from the group consisting of: naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, indole, benzothiophene, benzofuran, benzimidazole, indazole, benzoxazole, benzisoxazole, benzthiazole, benzisothiazole, purine, indoline[[,]] and isoindoline.

23. (Currently amended) A method according to claim 6 wherein R₂ and R'₂ are joined to form cyclic structures selected from the group consisting of : pyrrolidine, piperidine, hexahydro-1H-azepine, morpholine ~~or~~ and piperazine.

24. (Currently amended) A method according to claim 6 wherein Y₁ is selected from the group consisting of: croman, isochroman, benzofuran, cromene, 1,2,3,4-tetrahydronaphthalene, 1,4-dihydronaphthalene, indan, indene, benzopiperidine, indoline, isoindoline, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline or pteridine, coumarin ~~or~~ and 2,3-dihydrocoumarin.

25. (Currently amended) A method according to claim 6 wherein Y₂ is selected from the group consisting of: 9H-xanthone, 9H-xanthene, phenoxathiin, phenoxathiin-10-oxide, phenoxathiin-10-dioxide, acridine, phenazine, phenothiazine, phenoxazine, phenothiazine-5-oxide, phenothiazine-5-dioxide, thiathrene-5-dioxide, thiathrene-5-oxide, carbazole, dibenzo[b,d]furan[[,]] and dibenzo[b,d]thiophene.

26-31. (Cancelled)

32. (Currently amended) A method for treating a patient suffering from one or more insulin related ailments selected from the group consisting of ~~hyperglycemia~~, hypoglycemia, insulinomas, insulin and hypoglycemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism, ~~Alzheimer's disease~~, which method comprises the step of: administering to a patient in need thereof a therapeutically effective amount of a non-peptidyl compound which possesses one or more ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location of at least an ionic or a hydrophobic amino acid residue of insulin, wherein said compound is an insulin antagonist.

33. (Previously presented) A method according to claim 32, wherein the ionic amino acid residue is selected from the group consisting of: A21 Asn, B21 Glu and A17 Glu.

34. (Previously presented) A method according to claim 32, wherein the ionic and hydrophobic amino acid residue(s) is(are) selected from the group consisting of: A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr, A2 Ile, A3 Val and A1 Gly.

35. (Previously presented) A method according to claim 32, wherein at least one amino acid is selected from the group consisting of: A17 Glu, B21 Glu and A21 Asn; and at least

one amino acid is selected from the group consisting of: B24 Phe, B25 Phe, A19 Tyr, B12 Val and B16 Tyr.

36. (Previously presented) A method according to claim 32, wherein the non-peptidyl compound possesses ionic and hydrophobic chemical moieties spatially located so as to mimic ionic and hydrophobic residues associated with at least one of the following groups of amino acid residues:

- (i.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe;
- (ii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe;
- (iii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A1 Gly, A2 Ile, A3 Val;
- (iv.) A21 Asn, B21 Glu, A17 Glu, A19 Tyr, A1 Gly, A2 Ile, A3 Val;
- (v.) A21 Asn, B21 Glu, A17 Glu, B12 Val, A1 Gly, A2 Ile, A3 Val;
- (vi.) A21 Asn, B21 Glu, B12 Val, A1 Gly, A2 Ile, A3 Val;
- (vii.) A21 Asn, B21 Glu, A17 Glu, B16 Tyr, A1 Gly, A2 Ile, A3 Val;
- (viii.) A21 Asn, B21 Glu, A17 Glu, A19 Tyr, B12 Val, B16 Tyr;
- (ix.) A21 Asn, B21 Glu, A19 Tyr, B12 Val, B16 Tyr;
- (x.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xi.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B12 Val, B16 Tyr;
- (xiii.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xiv.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xv.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xvi.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, A19 Tyr;
- (xvii.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, B12 Val;
- (xviii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B12 Val;
- (xix.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, B12 Val;
- (xx.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, B12 Val;

- (xxi.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxii.) A21 Asn, B21 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxiii.) A21 Asn, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxiv.) B21 Glu, A17 Glu, B24 Phe, B25 Phe, B16 Tyr;
- (xxv.) A21 Asn, B21 Glu, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxvi.) A21 Asn, B21 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxvii.) A21 Asn, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxviii.) B21 Glu, A17 Glu, B24 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxix.) A21 Asn, B21 Glu, A17 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxx.) A21 Asn, B21 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr;
- (xxxi.) A21 Asn, A17 Glu, B25 Phe, A19 Tyr, B12 Val, B16 Tyr; and
- (xxxii.) B21 Glu, A17 Glu, B25 Phe, A19 Tyr, B12 Val.

37. (Currently amended) A method according to claim 32, wherein the non-peptidyl compound has the following formula:



where A is W or VXW;

V is V₁ or V₂;

V is substituted with up to two X groups;

V₁ is a phenyl or 6 membered heteroaromatic ring, optionally substituted with up to 5 R₁ groups;

V₂ is a 5 member ring system which may incorporate up to 4 hetero atoms which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R₂, oxygen or sulfur, the ring system being optionally substituted with up to 4 R₁ groups;

W is W₁ or W₂ or W₃;

W is substituted with up to two X groups;

W₁ is V₁;

W₂ is a fused bicyclic ring system comprising rings of 5 or 6 atoms, which may incorporate up to 4 hetero atoms, which may be independently a nitrogen atom, a

nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the system being optionally substituted with up to seven R_1 groups;

W_3 is $-N(R_2)R'_2$;

R_1 is independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, haloalkyl, haloalkoxy, halogen, SH, thioalkyl, cyano (-CN), $N(R_2)R'_2$, phenyl, phenyl optionally substituted with up to five alkyl groups of 1 to 3 carbon atoms or up to five halogen atoms, benzyl, phenethyl, nitro, $-COR_3$, $-R_5COR_3$, $-R_5SOR_3$, $-R_5SO_2R_3$, $-SO_2N(R_2)R'_2$ or azido;

R_2 and R'_2 are independently H, alkyl of 1 to 6 carbon atoms, alkenyl of 3 to 6 carbon atoms, alkynyl of 3 to 6 carbons, hydroxyalkyl of 2 to 6 carbons, alkoxy of 2 to 6 carbons, haloalkyl, haloalkenyl, haloalkoxy, benzyl, benzyl optionally substituted with up to four R_1 groups, phenylethyl, phenylethyl optionally substituted with up to four R_1 groups, arylalkyl, and where R_2 and R'_2 can also be joined to form cyclic structures;

R_3 is independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, $-R_4N(R_2)R'_2$, mesyl, trifluoromesyl, $-NHSO_2CH_3$ or $-NHSO_2CF_3$;

R_4 is independently a bond, alkyl, alkenyl or alkynyl;

X is independently, a bond, $-R_4N(R_2)R_4-$, $-R_4N=NR_4-$, $-R_4N(R_2)-N(R_2)R_4-$, $-R_4OR_4-$, $-R_4SR_4-$, $-R_5-$, $-R_5O-$, $-R_5S-$, $-R_5N(R_2)-$, $-SO-$, sulfonyl ($-SO_2-$), $-CO-$, $-CONH-$, $-NHCONH-$, $-NHCO-$, $-CONHCO-$, $-CON(R_2)-$, $-R_5COR_5-$, $-R_5COR_5N(R_2)R_5-$, $-N(R_2)CO-$ or $-R_4N(R_2)R_4COR_4-$;

R_5 is independently alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy;

Y is either Y_1 , Y_2 or Y_3 ;

Y is substituted with at least two, but optionally up to four X linking groups;


Y_1 is a fused bicyclic ring system comprising rings of 5 or 6 atoms which may incorporate up to 4 hetero atoms, which may be independently a nitrogen atom, a nitrogen atom optionally substituted with R_2 , oxygen or sulfur, the ring system optionally independently incorporating a sulfoxide (SO), sulfone (SO_2) or carbonyl (CO) group and optionally up to seven R_1 groups;

Y_2 is a 6:6:6 or a 6:5:6 fused tricyclic system which may incorporate up to 4 hetero atoms which may be independently a nitrogen atom, a nitrogen atom optionally

substituted with R_2 , oxygen or sulfur, the ring system optionally independently incorporating a sulfoxide (SO), sulfone (SO_2) or carbonyl (CO) group, and the ring system being substituted with at least two, but optionally up to four X linking groups and optionally up to seven R_1 groups;

Y_3 is V_1 ;

Z is independently $-R_6COOH$, $-R_6SO_3H$, $-R_6NO_2$, $-R_6SO_2H$, $-R_6SO_2NHR_2$, $-R_7SO_2NHCOR_4$, -N-trifluoromesylsulfonamidate, -OH, -2-yl-hydroxyethanoic acid ($-\text{CH}(\text{OH})\text{COOH}$), -3-yl-2-hydroxypropanoic acid ($-\text{CH}_2\text{CH}(\text{OH})\text{COOH}$) -2-yl-2-hydroxypropanoic acid ($-\text{CH}(\text{CH}_3)(\text{OH})\text{COOH}$), -3-yl-2,3-dihydroxypropanoic acid ($-\text{CH}(\text{OH})\text{CH}(\text{OH})\text{COOH}$), -2-yl-2,3-dihydroxypropanoic acid ($-\text{C}(\text{CH}_2(\text{OH}))(\text{OH})\text{COOH}$), -3-yl-2-hydroxypropan-3-one-1-oic acid ($-\text{COCH}(\text{OH})\text{COOH}$, 2-yl-2-hydroxypropandioic acid ($-\text{C}(\text{COOH})(\text{OH})\text{COOH}$), -2-yl-propandioic acid ($-\text{C}(\text{COOH})(\text{H})\text{COOH}$), -4-yl-2-hydroxybutan-4-one-1-oic acid ($-\text{COCH}_2\text{CH}(\text{OH})\text{COOH}$, 2-yl-2-hydroxybutan-1,4-dioic acid ($-\text{C}(\text{OH})(\text{COOH})\text{CH}_2\text{COOH}$), 3-yl-2-hydroxybutan-1,4-dioic acid ($-\text{CH}(\text{CH}(\text{OH})\text{COOH})\text{COOH}$), 5-yl-tetrazole,



R_6 is independently a bond, alkyl, alkenyl, alkynyl, alkoxy, $-\text{CO}(\text{CH}_2)_n-$, where n is an integer between 0 and 4, alkanolic, alkenolic or alkynolic; with the exception that where W_1 is an optionally substituted phenyl then Y_3 cannot be an optionally substituted phenyl.

38. (Previously presented) A method according to claim 37, wherein the non-peptidyl compound is a dimer or heterodimer wherein the compounds are joined through a X linking group by way of their V or W groups.

39. (Currently amended) A method according to claim 37, wherein when V is V_1 or V_2 , then:

V_1 is selected from the group consisting of, benzene, pyridine, pyridazine, pyrimidine, pyrazine ~~or~~ and triazine and is optionally substituted with up to 5 R_1 groups; and

V₂ is selected from the group consisting of, cyclopenta-1,3-diene, pyrrole, furan, thiophene, oxazole, isoxazole, pyrazole, imidazole, thiazole, isothiazole ~~or~~ and triazole and is optionally substituted with up to 4 R₁ groups;

and W is W₂ then

W₂ is selected from the group consisting of naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, indole, benzothiophene, benzofuran, benzimidazole, indazole, benzoxazole, benzisooxazole, benzthiazole, benzisothiazole, purine, indoline ~~or~~ and isoindoline and is optionally substituted with up to seven R₁ groups;

and Y is either Y₁ or Y₂ then

Y₁ is selected from the group consisting of croman, isochroman, benzofuran, cromene, 1,2,3,4-tetrahydronaphthalene, 1,4-dihydronaphthalene, indan, indene, benzopiperidine, indoline, isoindoline, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline or pteridine, coumarin ~~or~~ and 2,3-dihydrocoumarin and is optionally substituted with up to seven R₁ groups; and

Y₂ is selected from the group consisting of 9H-xanthone, 9H-xanthene, phenoxathiin, phenoxathiin-10-oxide, phenoxathiin-10-dioxide, acridine, phenazine, phenothiazine, phenoxazine, phenothiazine-5-oxide, phenothiazine-5-dioxide, thiathrene-5-dioxide, thiathrene-5-oxide, carbazole, dibenzo[b,d]furan ~~or~~ and dibenzo[b,d]thiophene and is optionally substituted with up to seven R₁ groups.

40. (Previously presented) A method according to claim 37, wherein when A is VXW then: V is phenyl or pyrazole, optionally substituted with up to 5 R₁ groups; and when A is W or VXW then W is W₁, W₂ or W₃ wherein W₁ is phenyl optionally substituted with up to 5 R₁ groups;

W₂ is naphthalene or quinoline optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

W₃ is -N(R₂)R₂ wherein R₂ is propyl; X is independently, a bond, methoxy (-OCH₂-), oxypropoxy (-O(CH₂)₃O-), hexenyloxy (-O(CH₂)₄CH=CH-), sulfonyloxy (-SO₂O-),

methyl (-CH₂-), amidyl (-CONH-) or -NHCONH-; and Y is either Y₁ or Y₂ then Y₁ is croman, 4-H-chromen-4-one or naphthalene optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

Y₂ is 9H-xanthone optionally substituted with up to seven R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl;

Y₃ is phenyl optionally substituted with up to 5 R₁ groups wherein R₁ is independently H, OH, methyl, ethyl, propyl, nitro, methoxy, ethoxy, 2-hydroxyethoxy, chloro, fluoro or acetyl; and

Z is independently -R₆COOH, -R₆SO₃H or -N-trifluoromesylsulfonamidate wherein R₆ is independently a bond or propyl.

41. (Currently amended) A method according to claim 37, wherein the non-peptidyl compound is selected from the following group of compounds:

- (i.) 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylic acid];
- (ii.) 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid;
- (iii.) 2,4-dichloro-6-(N-(trifluoromethanesulfonyl))sulfamoylphenyl 3,5-dichloro-2-hydroxybenzenesulfonate;
- (iv.) 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid;
- (v.) 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid;
- (vi.) 3,4-dihydro-8-propyl-7-[[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propyl]oxy]-2H-1-benzopyran-2-carboxylic acid;
- (vii.) 3,4-dihydro-8-propyl-7-[[3-[2-ethyl-5-hydroxy-4-ethoxyphenoxy]propyl]oxy]-2H-1-benzopyran-2-carboxylic acid;
- (viii.) 3-[4-[7-carboxy-9-oxo-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9H-xanthene]]propanoic acid; or

(ix.) 8-propyl-7-(quinol-2'-ylmethoxy)-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid;

(x.) 7-(naphth-2'-ylmethoxy)-8-propyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; (xi.) N-(trifluoromethanesulfonyl)-3,5-dinitro-4-(N',N'-

dipropylamino)benzenesulfonamide;

(xii.) 8-propyl-7-[3-[4-(4-fluorophenyl)-2-ethyl-5-hydroxyphenoxy]propoxy]-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid;

(xiii.) 3,4-dihydro-7-[[6-(4-methoxyphenyl)hexenyl]oxy]-8-propyl-2H-1-benzopyran-2-carboxylic acid; ~~or~~ and

(xiv.) 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid.

42. (Currently amended) A method according to claim 37 wherein V₁ is selected from the group consisting of: benzene, pyridine, pyridazine, pyrimidine, pyrazine [[,]] and triazine.

43. (Currently amended) A method according to claim 37 wherein V₂ is selected from the group consisting of: cyclopenta-1,3-diene, pyrrole, furan, thiophene, oxazole, isoxazole, pyrazole, imidazole, thiazole, isothiazole ~~or~~ and triazole, optionally substituted with up to 4 R₁ groups.

44. (Currently amended) A method according to claim 37 wherein W₂ is selected from the group consisting of: naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, indole, benzothiophene, benzofuran, benzimidazole, indazole, benzoxazole, benzisooxazole, benzthiazole, benzisothiazole, purine, indoline[[,]] and isoindoline.

45. (Currently amended) A method according to claim 37 wherein R₂ and R'₂ are joined to form cyclic structures selected from the group consisting of: pyrrolidine, piperidine, hexahydro-1H-azepine, morpholine ~~or~~ and piperazine.

46. (Currently amended) A method according to claim 37 wherein Y₁ is selected from the group consisting of: croman, isochroman, benzofuran, cromene, 1,2,3,4-tetrahydronaphthalene, 1,4-dihydronaphthalene, indan, indene, benzopiperidine, indoline,

isoindoline, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline or pteridine, coumarin or and 2,3-dihydrocoumarin.

47. (Currently amended) A method according to claim 37 wherein Y_2 is selected from the group consisting of: 9H-xanthone, 9H-xanthene, phenoxathiin, phenoxathiin-10-oxide, phenoxathiin-10-dioxide, acridine, phenazine, phenothiazine, phenoxazine, phenothiazine-5-oxide, phenothiazine-5-dioxide, thiathrene-5-dioxide, thiathrene-5-oxide, carbazole, dibenzo[b,d]furan[,]and dibenzo[b,d]thiophene.